Circulating adipokines data associated with insulin secretagogue use in breast cancer patients

Zachary A P Wintrob, Jeffrey P. Hammel, George K. Nimako, Zahra S. Fayazi, Dan P. Gaile, Alan Forrest, Alice C. Ceacareanu

Research output: Research - peer-reviewArticle

  • 4 Citations

Abstract

Oral drugs stimulating endogenous insulin production (insulin secretagogues) may have detrimental effects on breast cancer outcomes. The data presented shows the relationship between pre-existing insulin secretagogues use, adipokine profiles at the time of breast cancer (BC) diagnosis and subsequent cancer outcomes in women diagnosed with BC and type 2 diabetes mellitus (T2DM). The Pearson correlation analysis evaluating the relationship between adipokines stratified by T2DM pharmacotherapy and controls is also provided. This information is the extension of the data presented and discussed in “Insulin use, adipokine profiles and breast cancer prognosis” (Wintrob et al., in press) [1].

LanguageEnglish (US)
Pages238-247
Number of pages10
JournalData in Brief
Volume10
DOIs
StatePublished - Feb 1 2017

Fingerprint

cancer
chronic illness
drug
time

Keywords

  • Adipokine
  • Breast cancer
  • Cancer outcomes
  • Cancer prognosis
  • Diabetes
  • Insulin
  • Secretagogue

ASJC Scopus subject areas

  • Education
  • General

Cite this

Wintrob, Z. A. P., Hammel, J. P., Nimako, G. K., Fayazi, Z. S., Gaile, D. P., Forrest, A., & Ceacareanu, A. C. (2017). Circulating adipokines data associated with insulin secretagogue use in breast cancer patients. Data in Brief, 10, 238-247. DOI: 10.1016/j.dib.2016.11.060

Circulating adipokines data associated with insulin secretagogue use in breast cancer patients. / Wintrob, Zachary A P; Hammel, Jeffrey P.; Nimako, George K.; Fayazi, Zahra S.; Gaile, Dan P.; Forrest, Alan; Ceacareanu, Alice C.

In: Data in Brief, Vol. 10, 01.02.2017, p. 238-247.

Research output: Research - peer-reviewArticle

Wintrob, ZAP, Hammel, JP, Nimako, GK, Fayazi, ZS, Gaile, DP, Forrest, A & Ceacareanu, AC 2017, 'Circulating adipokines data associated with insulin secretagogue use in breast cancer patients' Data in Brief, vol 10, pp. 238-247. DOI: 10.1016/j.dib.2016.11.060
Wintrob ZAP, Hammel JP, Nimako GK, Fayazi ZS, Gaile DP, Forrest A et al. Circulating adipokines data associated with insulin secretagogue use in breast cancer patients. Data in Brief. 2017 Feb 1;10:238-247. Available from, DOI: 10.1016/j.dib.2016.11.060
Wintrob, Zachary A P ; Hammel, Jeffrey P. ; Nimako, George K. ; Fayazi, Zahra S. ; Gaile, Dan P. ; Forrest, Alan ; Ceacareanu, Alice C./ Circulating adipokines data associated with insulin secretagogue use in breast cancer patients. In: Data in Brief. 2017 ; Vol. 10. pp. 238-247
@article{a04e243f18e146519b27f0e5a5b8182b,
title = "Circulating adipokines data associated with insulin secretagogue use in breast cancer patients",
abstract = "Oral drugs stimulating endogenous insulin production (insulin secretagogues) may have detrimental effects on breast cancer outcomes. The data presented shows the relationship between pre-existing insulin secretagogues use, adipokine profiles at the time of breast cancer (BC) diagnosis and subsequent cancer outcomes in women diagnosed with BC and type 2 diabetes mellitus (T2DM). The Pearson correlation analysis evaluating the relationship between adipokines stratified by T2DM pharmacotherapy and controls is also provided. This information is the extension of the data presented and discussed in “Insulin use, adipokine profiles and breast cancer prognosis” (Wintrob et al., in press) [1].",
keywords = "Adipokine, Breast cancer, Cancer outcomes, Cancer prognosis, Diabetes, Insulin, Secretagogue",
author = "Wintrob, {Zachary A P} and Hammel, {Jeffrey P.} and Nimako, {George K.} and Fayazi, {Zahra S.} and Gaile, {Dan P.} and Alan Forrest and Ceacareanu, {Alice C.}",
year = "2017",
month = "2",
doi = "10.1016/j.dib.2016.11.060",
volume = "10",
pages = "238--247",
journal = "Data in Brief",
issn = "2352-3409",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Circulating adipokines data associated with insulin secretagogue use in breast cancer patients

AU - Wintrob,Zachary A P

AU - Hammel,Jeffrey P.

AU - Nimako,George K.

AU - Fayazi,Zahra S.

AU - Gaile,Dan P.

AU - Forrest,Alan

AU - Ceacareanu,Alice C.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Oral drugs stimulating endogenous insulin production (insulin secretagogues) may have detrimental effects on breast cancer outcomes. The data presented shows the relationship between pre-existing insulin secretagogues use, adipokine profiles at the time of breast cancer (BC) diagnosis and subsequent cancer outcomes in women diagnosed with BC and type 2 diabetes mellitus (T2DM). The Pearson correlation analysis evaluating the relationship between adipokines stratified by T2DM pharmacotherapy and controls is also provided. This information is the extension of the data presented and discussed in “Insulin use, adipokine profiles and breast cancer prognosis” (Wintrob et al., in press) [1].

AB - Oral drugs stimulating endogenous insulin production (insulin secretagogues) may have detrimental effects on breast cancer outcomes. The data presented shows the relationship between pre-existing insulin secretagogues use, adipokine profiles at the time of breast cancer (BC) diagnosis and subsequent cancer outcomes in women diagnosed with BC and type 2 diabetes mellitus (T2DM). The Pearson correlation analysis evaluating the relationship between adipokines stratified by T2DM pharmacotherapy and controls is also provided. This information is the extension of the data presented and discussed in “Insulin use, adipokine profiles and breast cancer prognosis” (Wintrob et al., in press) [1].

KW - Adipokine

KW - Breast cancer

KW - Cancer outcomes

KW - Cancer prognosis

KW - Diabetes

KW - Insulin

KW - Secretagogue

UR - http://www.scopus.com/inward/record.url?scp=85017314903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017314903&partnerID=8YFLogxK

U2 - 10.1016/j.dib.2016.11.060

DO - 10.1016/j.dib.2016.11.060

M3 - Article

VL - 10

SP - 238

EP - 247

JO - Data in Brief

T2 - Data in Brief

JF - Data in Brief

SN - 2352-3409

ER -